Contrast-associated acute kidney injury (CA-AKI) is a major concern when iodinated contrast material is administered, especially in patients at risk. Efforts have been undertaken to understand the detrimental effects of contrast media (CM). With the use of low-osmolar or iso-osmolar CM the incidence of CA-AKI has steadily decreased within the past decade; however, especially in the pediatric population information is scarce. Incidence rates have been reported to range between 0% to 18.75%, particularly depending on indication, selection of population (i.e. preexisting co-morbidities), and definition of AKI. Different biomarkers have been proposed, but confirmatory studies are either lacking or have contributed to their lack of diagnostic power. Proteomic approaches have been employed and may pave the way to such discovery. Prevention strategies have been tested and proposed, but the recently published AMACING and PRESERVE trials have shown that commonly used strategies (such as systematic hydration or administration of N-acetylcysteine) have no role in the prevention of CA-AKI. We propose that thoughtful assessment of one's fluid state is the most appropriate approach and depending on the hydration status diuretics or fluid administration should be provided to achieve an euvolemic state ahead of contrast exposure.
Introduction
The incidence of acute kidney injury (AKI) in childhood is rising and its epidemiology has changed significantly over the past decades. Concurrent with technologic improvements in pediatric intensive care, a shift from pri mary renal causes, sepsis, and burns to renal ischemia (predominantly in the setting of cardiac surgery) and nephrotoxin exposure has been noted. There fore, hospitalized children increasingly develop AKI not from primary kidney disease but concomitant with other systemic illness or related to treatment 1) .
Over the past decades, formidable advances in radiology have greatly im proved the practice of medicine, and the frequency of diagnostic and inter ventional imaging remains on the rise 2) . The use of contrast media (CM) is either indispensable in this context (e.g. coronary angiography) or greatly improves the diagnostic accuracy of the examination. Therefore, apart from radiation exposure, allergic reactions and renal toxicity remain limitations of radiological interventions.
Contrastassociated acute kidney injury (CAAKI) refers to the sudden deterioration in renal function following contrast exposure in the absence of other causes. The un derlying pathophy siology is incompletely understood. Etiologic factors that have been incriminated include va soconstriction and direct tubular toxicity. CAAKI has repeatedly been linked with adverse outcomes, such as length of hospital stay, inhospital mortality and risk of chronic kidney disease (CKD) in later life.
Notably, causality cannot be inferred from this sequence and few studies in the field had a suitable control group to permit separation of genuine contrastinduced nephro pathy from CAAKI. Although the administration of iodi nated CM is considered a major risk factor for the develop ment of AKI, numerous recent publications have questioned the danger of modern radioagents, and there is emerging consensus, that the risk of CAAKI has been vastly overem phasized. Furthermore, compared with individuals with multifactorial AKI, patients with CAAKI appear to be more likely to experience only mild decrements in kidney function that recover completely 3) .
Contrast nephrotoxicity is practically nonexistent in isolation and usually develops in association with conco mitant insults such as hypotension, dehydration, admini stration of other nephrotoxins (e.g. antibiotics), and under lying comorbidities 4, 5) . The coexistence of several such triggers is not uncommon, particularly in the intensive care unit (ICU). Naturally, ascribing AKI to one specific cause frequently remains elusive.
Preexisting renal disease is the greatest independent risk factor for CAAKI; furthermore, diabetes and advanced age predispose adult patients to CAAKI. Type and volume of CM are independent and potentially modifiable predic tors for the development of CAAKI. In the pediatric pop ulation, such predisposing factors are less well defined. Ostensibly, children might carry a lower background risk; however, they exhibit their own unique risk factors, such as prematurity and congenital organ anomalies, as dis cussed below.
Evaluation of kidney function in children and definition of pediatric CA-AKI
There is no gold standard for estimating the glomerular filtration rate (GFR) in children, and the limitations of serum creatinine in this context, its rate of production being proportional to muscle mass, are obvious. Although various formulas for estimating GFR exist, the Bedside Schwartz equation (estimated GFR=[0.413×height)/ serum creatinine]), valid in children from 1 to 16 years, remains the most practicable method in pediatrics. In 2004, the Acute Dialysis Quality Initiative (ADQI) termed the RIFLE criteria (risk, injury, failure, loss of function, endstage renal disease). Three years later, a pediatric modified RIFLE (pRIFLE) AKI definition was developed in critically ill children 6) .
There is ongoing debate about the ideal definition of AKI in children. A new creatininebased criterion for pediatric AKI (termed pROCK) defines AKI as a creatinine increase of both ≥20 µmol/l and ≥30% over the initial value within 7 days. This was tested in 102,817 Chinese children and compared to the KDIGO and pRIFLE criteria. The authors identified AKI in 5432 (5.3%), 10,446 (10.2%) and 15.647 (15.2%) of participants when using the pROCK, KDIGO and the pRIFLE definitions 7) . Differences in the occurrence of AKI have also been reported among children with hos pitalization. In line, the pRIFLE criterion found the highest rate of AKI (51.1%) as compared to 40.3% and 37.3% with the KDIGO and AKIN criteria, respectively 8) .
However, serum creatinine is an imperfect marker for the diagnosis of AKI in general and of CAAKI in parti cular. Numerous novel biomarkers are being scrutinized, and candidates include neutrophil gelatinaseassociated lipocalin (NGAL), kidney injury molecule1 (KIM1), in terleukin18 (IL18) and livertype fatty acidbinding pro tein (LFABP) 9, 10) . For instance, Hirsch and coworkers ob served substantial upregulation of urine and plasma NGAL 2 hours after CM in a patient population undergoing cardiac catheterization, which predicted occurrence of contrast nephropathy. 91 children were included prospectively and NGAL was measured at baseline and after 2 and 6 hours. A significant increase in urinary and plasma NGAL was observed as early as 2 hours after contrast administration in those with CAAKI, which was defined as a 50% or greater increase in serum creatinine (11 subjects) . Using a cutoff value of 100 ng/mL yielded in an excellent sensitivity, specificity and area under the receiveroperating charac teristic (AUC) for the 2hour urine NGAL (73%, 100%, and 0.92) and 2hour plasma NGAL (73%, 100%, and 0.91, re spectively). Measurement of NGAL was found to be the most powerful predictor of childhood CAAKI in this investigation 11) . In contrast, another study recruiting 50 children undergoing cardiac catheterization found CA AKI in 16 subjects within a period of 24 hours and reported a comparable increase in serum NGAL within the first 6 hours in both, the AKI and the nonAKI group 12) .
No CAAKI event was observed in a small study from Korea including 26 children undergoing cardiac catheteri zation. In line, urinary NGAL remained stable over 48 hours of followup, while the authors observed a steady in crease of urine KIM1, and a transient increase of LFABP. The former increase became irrelevant when adjusted for urinary creatinine excretion. In the absence of meaningful creatinine changes, the authors concluded that LFABP may be a useful biomarker to detect subclinical AKI 9) .
A study of 123 children and adolescents with a prospec tive followup included one group (n=58) receiving angio graphy with iopromide and one group (n=65) undergoing magnetic resonance (MR) angiography/urography with gadolinium (Gd)based CM. CAAKI occurred in two pa tients in the iopromide group (3.9%), while 9.7% (6 patients) in the second group developed AKI. In the prediction of AKI normalized urinary KIM1 showed the most convin cing results with a AUC at 24 hours of 0.76 (sensitivity 83.3 % and specificity of 54.2%). Other markers, such as NGAL and urinary NGAL could not predict CAAKI accurately 13) .
Ideally a biomarker predicts the risk of CAAKI at base line. A proteomic approach was chosen to identify such markers and ten children developed AKI within 24 hours of cardiac catheterization compared to seven without. The absence of the 41 amino acidvariant of human betade fensin1 yielded an AUC of 0.89-0.99 and the presence of a 4631 Da large marker had an AUC of 0.84 14) . Together, both markers may provide an accurate forecast identifying children at risk to develop AKI following contrast exposure.
A prospective study of children undergoing cardiac sur gery without preoperative AKI examined the differences between a creatininedefined versus a cystatin Cdefined AKI incidence. The authors found a substantially lower incidence of AKI when cystatin C was used to define AKI and in those with AKI interleukin18 and KIM1 as putative biomarkers more closely correlated with this definition 15) .
Taken together, the predictive value of proposed markers of CAAKI is controversial and more research in this direc tion with a larger sample size is needed. In line, uniform definition of AKI in this context is also necessary to directly compare different studies with each other. Whether a cy statin Cbased definition of AKI is more informative and more closely associates with biomarkers needs to be tested in future trials.
AKI in children
AKI is a frequent comorbidity experienced by hospita lized children and exposure to nephrotoxic agents 16) . Next to antibiotics such as aminoglycosides and vancomycin, CM ranks among the most common potential culprits prescribed to exposed individuals 17) . In the ICU setting, various factors such as sepsis, cardiac dysfunction, dehydra tion or volume overload, may compromise renal blood flow.
It is estimated that drugs, including contrast agents, con tribute to approximately 15% of all AKI cases in adults but children are usually less prone to nephrotoxicity 18) .
The Nephrotoxic Injury Negated by Justintime Action (NINJA) recently reported a high prevalence of nephrotoxin use following congenital heart disease (CHD) surgery 18) . Nephrotoxins were defined according to prespecified cri teria, and this list included CM. Although no association between high nephrotoxin exposure and AKI was observed, this was ascribed to the multitude of competitive renal in sults. The authors conclude that nephrotoxin exposure may represent a modifiable risk factor for AKI in high risk individuals.
In an Israeli single center study performed on a neonatal ICU the authors demonstrated underreporting of AKI, with episodes of kidney injury often not recorded in pati ents' medical files 19) . This is of particular concern, because over the past decade the longterm consequences of AKI have garnered increased attention and several cohort studies demonstrate that pediatric AKI is a gateway for proteinuria, hypertension, and CKD in later life. This association seems to be dosedependent, i.e. individuals with more severe forms of AKI show a higher risk for progression to CKD.
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Specific pediatric risk factors
In recent times, the impact of prematurity on future kid ney health has attracted attention, and it is now established that children born at low birth weight show an increased risk for CKD in adulthood 20) . With 50,000 infants born each year at less than 28 weeks of gestation in the United States alone, the prospective impact of this trend cannot be overestimated. Reduced global nephron mass and incom plete nephrogenesis are underlying mechanisms. Subse quent postnatal events, such as infections, may further impair the development of intact tubular structures, and render individuals prone to tubular damage, when exposed to nephrotoxic agents 20) .
CHD constitutes the most common congenital disorder in neonates. Critical CHD, defined as need for surgery or catheterbased intervention in the first year of life, occurs in approximately one quarter of such individuals 21) . Con genital anomalies of kidneys and urinary tract (CAKUT) represent another sizeable proportion of anomalies iden tified prenatally and are a major cause of endstage renal disease (ESRD) in children 22) . For obvious reasons, both entities are associated with an increased longterm need for radiologic procedures. A vast array of other forms of con genital kidney diseases, such as idiopathic nephrotic synd rome and hereditary tubulopathies, though rare individu ally, amount to a substantial number of children with CKD in specialist centers. Lastly, pediatric transplant recipients are another vulnerable cohort posing unique challenges 23) .
Incidence of pediatric CA-AKI
Few studies have specifically examined CAAKI in pe diatric populations. In the trial by Hwang et al., no increase in serum creatinine levels was observed in a cohort with normal kidney function, corroborating the safety of CM in patients without CKD 9) . Along similar lines, a study from a trauma center, evaluating the incidence of CAAKI in severely injured pediatric patients (n=211), showed no dif ference in the incidence of contrast nephropathy between a noncontrast group and a group exposed to CM (8.5% vs. 7.3%, P value=0.76) 24) . Two recent trials reported incidences of pediatric CAAKI between 410%, but, as is frequently the case in this context, the lack of controls does not permit to draw causal inference from these results 25) . A study by Bedoya et al. 26) , involving 140 neonates (age 0-30 days), with 59 receiving intravenous iodinated CM, found no evidence of contrast nephrotoxicity when compared to propensitymatched control groups, not exposed to CM. Recently, McDonald et al. were able to replicate this finding in the largest cohort reported to date. Among 2,201 pedia tric patients (mean age 15 years), outcomes were compared between individuals who received contrastbased com puted tomography (CT)imaging (n=1,773) versus patients who received noncontrast scans (n=428). Demographics were not balanced among the two groups, with more ICU admissions in the group receiving CM, while predisposing comorbidities were more frequent in the noncontrast scan group (i.e. CKD and calcineurin inhibitor use). AKI and dialysis occurred in 3.3% and 0.1%, respectively, with no significant difference between the two groups. Of note, all patients with postCT stage 3 AKI also had contrastinde pendent causes of AKI, such as hypovolemia, hypotension, and nephrotoxic medications. However, only a minority of patients (n=145) had an estimated GFR <60 ml/min/1.73 m 2 , limiting the generalizability of these data 27) (see Table  1 for further details).
On the whole, the true incidence of contrast nephroto xicity in pediatrics appears to be very low and in patients with normal kidney function, the risk of CAAKI seems negligible.
Prevention
There are no evidencebased guidelines for CAAKI prevention in children. In the adult population, a large number of intervention studies has been performed in this field; such studies are scarce in children. Therefore, preven tive strategies in pediatrics frequently extrapolate data from the adult literature, and it can often only be assumed that such measures also provide some degree of protection for children (and do no harm). Moreover, highquality trials with adequate followup and clinically meaningful end points beyond "delta creatinine at day 7" have only recently started to emerge in the adult literature and frequently challenge purported standards of care. For instance, the benefit of preventive approaches in adults has been seri ously questioned by two recent highprofile trials, namely AMACING and PRESERVE 28, 29) ; as an aside, overall AKI risk was remarkably low in both studies, despite their pur ported highrisk cohorts.
Type of contrast
The past four decades have seen a continuous decrease of osmolality of contrast agents, reaching physiologic levels with isoosmolar agents (IOCM) such as iodixanol. Follo wing a metaanalysis by Barrett and Carlisle, published in 1993, the use of hyperosmolar CM (HOCM) has largely been abandoned 30) . In a large Italian cohort undergoing percutaneous coronary intervention, there were no diffe rences in the adjusted risk of CAAKI across 4 lowosmolar CM (LOCM), compared with iodixanol, suggesting that overall risk is low with all modern contrast agents 31, 32) . In line, Zo'o and colleagues performed a trial comparing the LOCM iobitrol with iodixanol. 128 children (age 8.7±4.7 years) undergoing CT were randomized and no significant difference of AKI was found in this low risk cohort 25) .
Volume of contrast
The amount of CM used is frequently cited as an inde pendent predictor for the development of contrast nephro pathy. However, according to the recent manual of the American College of Radiology (ACR), there is a lack of robust data to support a dosetoxicity relationship for intra venous (IV) iodinated CM, with only intraarterial CM showing a directly proportional relationship 33) . Very small volumes of contrast agents, typically 1.5-2ml/kg, are usu ally administered in neonates and infants 34) , and, as stated in a previous review, the "volume of contrast should be de termined by the size of the child, the imaging study being performed, and the estimated GFR" 35) . Nevertheless, it seems prudent to limit contrast volume in atrisk indivi duals, provided that the quality of diagnostic imaging is not jeopardized. An ALARA (as low as reasonably achie vable) concept is usually recommended.
Route of administration
The majority of data in the field of contrast nephropathy stems from cardiology studies. Unlike IV contrast admini stration, in coronary angiography the injection is intra arterial and suprarenal. Cholesterol emboli, dislodged by the catheter, are possible competitor strikes, and the kid neys are exposed to a more abrupt and concentrated CM dose. Consequently, a higher overall incidence of CAAKI is usually found in studies of cardiac angiography than in studies involving IV contrast administration. However, McDonald et al. recently reported a similar risk of AKI after intraarterial and IV administration of CM (9.9% versus 11%) in a large cohort of patients that received both routes of administration 36) . Despite this, patients undergoing such intraarterial procedures should be monitored with particular attention, because intraarterial angiography is associated with a higher risk of postcontrast AKI, re gardless of etiology.
Hydration
Fluid administration increases urine flow rate, reduces CM concentration in the tubule and expedites CM elimi Abbreviations: CM (contrast media), CA (coronary angiography), CT (computed tomography), RIFLE (risk, injury, failure, loss, ESRD), CrCl (creatinine clearance), CA-AKI (contrast-associated acute kidney injury), KDIGO (Kidney Disease Improving Global Outcomes), AKIN (Acute Kidney Injury Network). nation, thereby limiting exposure time of tubular cells to the deleterious effects of CM. Consequently, intravenous hydration is considered standard of care for patients at risk for CAAKI, with 0.9% normal saline (NS) being the most common utilized fluid. However, in the AMACING trial 28) , involving 660 adult patients with CKD stage 3, preventive hydration with NS not only failed to show benefit in terms of AKI risk but reported 13 episodes (4%) of symptomatic heart failure in the treatment group versus none in the control group. Along similar lines, Liu et al. observed an increased risk of CAAKI and death in patients with CKD with "excessively high hydration", as calculated by hydra tion volume to weight 37) . It seems obvious that children at increased risk for contrast nephropathy, such as patients with CHD, are also particularly prone to volume overload, so a cautionary approach regarding hydration is mandatory.
Limiting exposure of the kidney to radiocontrast by ge nerating high urine flow without causing hypovolemia ("forced diuresis") remains an accepted tool in preventing CAAKI; this concept is also cited in the pediatric literature 35) . In adults, the P.R.I.N.C.E. study 38) , published in 1999, provided evidence that "good urine output" (urine flow rates above 150 ml/h) following contrast exposure is asso ciated with a reduced risk of AKI. The study involved 98 patients with CKD stage 3-4 (median estimated creatinine clearance of 32 ml/min) undergoing elective coronary an giography. In hindsight, assessment of volume status in this study appears unduly invasive, with right heart cathe terization performed in all participants, and SwanGanz catheterization in individuals randomized to the experi mental arm; moreover, all patients had urinary catheters placed. Therefore, the practicality of this frequently cited paper seems questionable. The RenalGuard® system, a de vice delivering replacement solution in realtime and in an amount matched to urinary output, thereby maintaining euvolemia, is a relatively new strategy for CAAKI preven tion. It also involves placement of a urinary catheter; price issues and lack of data in children remain limitations 39) .
For all hydration strategies, the optimal type, quantity, timing, and duration of fluid administration remain largely unresolved issues and welldefined protocols are lacking, especially for children.
Pharmacologic strategies 1. No approved drugs exist for the prevention of CA-
AKI. NAcetylcysteine (NAC), a free radical scavenger anti oxidant, arguably represents the bestknown agent in the field of CAAKI prevention. The landmark paper by Tepel et al. 40) sparked a flurry of studies, which have been subject to a number of metaanalyses. Due to the heterogeneity of study designs, it was difficult to draw clear conclusions. Following the publication of the ACT trial and the PRESERVE study 29, 41) , both reporting no benefit of NAC in adult patients with CKD, this compound has lost much of its appeal. There are no publications pertaining to its use in the field of pediatric CAAKI. Some experts continue to use this agent in conjunction with hydration in children deemed at high risk for contrast nephropathy, although they acknowledge that this approach is not backed by the available literature, and its routine for AKI prophylaxis is not recommended. Notably, NAC should not be seen as a substitute for appropriate preprocedural patient screening and other measures, as outlined below.
Acetazolamide, a carbonic anhydrase inhibitor, has been proposed to be beneficial in the prevention of CAAKI. One study involving 96 pediatric patients with CKD (aged 3 to 19 years, mean creatinine clearance 52 ml/min/1.73 m 2 ), who underwent coronary angiograms, CT, or renal angio grams, found that urinary alkalinization with acetazola mide resulted in a lower incidence of postcontrast AKI than intravenous sodium bicarbonate (0.0 versus 8.7%; P=0,049) 42) . However, the difference in mean serum creatinine (1.32±0.13 mg/dL versus 1.39±0.14 mg/dL) 48 hours after contrast exposure, although statistically significant, is of doubtful clinical relevance. No corroborating evidence in pediatric cohorts has emerged since publication of this trial.
The alpha2receptor agonist dexmedetomidine is ap proved for sedation in adult ICU patients, but is increasingly used offlabel in the pediatric setting for various indica tions 43) . Its low risk of respiratory depression makes it a comparatively safe agent. In a murine model, alpha2re ceptor agonists exhibited renal protective effects following iohexol injection 44) . Attenuation of contrastmediated renal blood reduction after radiocontrast injection is a postulated mechanism 44) . The use of dexmedetomidine for the pre vention of AKI of diverse etiologies, including CAAKI, has been championed by a Turkish group. Bayram et al. 45) analyzed the effect of dexmedetomidine in a randomized, controlled trial (RCT) involving 60 children with CHD, scheduled for coronary angiography. The authors observed CAAKI (pRIFLE criteria) in 3 patients (10%) in the inter vention arm and in 11 (36.7%) in the control arm. Moreover, renin and NGAL levels at 24 hours after angiography were significantly lower in the dexmedetomidine group. Al though bradycardia was noted in 7 patients in the active arm as compared to 3 in the control group, this did not reach statistical significance. A recent metaanalysis of pharmacological interventions for AKI prevention after pediatric cardiac surgery reported a lower incidence of AKI in the dexmedetomidine groups (OR 0.65) 46) . Future trials should clarify the effectiveness of this agent for the preven tion of CAAKI and it remains to be seen, whether this drug will stand the test of time.
Numerous other agents have been evaluated, without showing benefit beyond single center trials 35) .
Given that multiple lines of evidence suggest that no single intervention strategy may successfully prevent CA AKI, a multimodal approach for renoprotection has been advocated 47) . We propose that currently physicians should identify atrisk groups, hold potentially nephrotoxic drugs prior to contrast administration, approach the interventio logist preemptively with a view to minimizing contrast vo lume, and target euvolemia.
Once CAAKI has occurred, management follows ge neral recommendations for AKI; in this context, it is im portant to avoid "second hits" i.e. repeat CM administra tion 48) .
CA-AKI: Much ado about little?
CAAKI is widely cited as a leading cause of inhospital AKI and its validity remains a clinical dogma. Newhouse et al. 49) were the first to observe that patients who were not exposed to iodinated contrast showed rates of AKI similar to patients with contrast nephropathy after CT. These au thors showed that controlling for potentially confounding clinical conditions that may trigger AKI is difficult and that a "post hoc, ergo propter hoc" reasoning has been in place for too long. Several recent publications 50, 51) , using propensity scorematching, have further challenged the doctrine of CAAKI as a standalone entity. Moreover, in hospitalized individuals, random changes in serum crea tinine ('background noise') may result in AKI misclassifi cation, irrespective of CM being present. Patients who re ceive contrast often have numerous other independent risk factors for AKI, either from their primary pathology or comorbidities, independent of contrast administration. As stated by Ehrmann et al. 52) , this distinction between a causal and an associative relationship between CM and AKI is of great importance, because suboptimal care may result from excessive caution ("renalism"). For fear of ne phrotoxicity, patients may undergo unenhanced imaging which is less accurate than contrastenhanced imaging, resulting in negative impact on clinical decisions related to treatment. Lastly, the bulk of negative trials in the field of CAAKI prevention could be regarded as another piece in the chain of evidence indicating that contrast nephropathy may be more fiction than fact.
Conclusion
In the absence of randomized controlled trials, wide spread lack of meaningful endpoints, and with only a handful of good quality papers available, it is difficult to make firm recommendations. Likewise, in view of the growing body of literature, the search for a single panacea to prevent contrast nephropathy in general and in pediatrics in particular will likely remain futile. Children at risk for AKI should be treated with due diligence, regardless of whether CAAKI is interpreted as contrastinduced AKI (i.e. a causative diagnosis) or postcontrast AKI (a correla tive diagnosis). This should entail a multimodal approach aimed at AKI prevention, close cooperation between care providers, and early (preemptive) nephrology consultation. www.chikd.org ORCID Andreas Kronbichler https://orcid.org/00000002 29452946
